Cinryze production has resumed

Shire plc announces unaudited results for the three months ended September 30, 2017. Flemming Ornskov, M.D., M.P.H., Shire CEO, commented:

“We delivered strong growth this quarter despite a Cinryze supply shortage. We experienced a product shortage of Cinryze during the quarter due to a manufacturing interruption at a third-party manufacturer. The issue has been addressed and production of Cinryze has resumed. Product was shipped to customers in early October. To enhance reliability of supply, we plan to start in-house production of Cinryze by Q1 2018, subject to FDA approval, as sustainable and unconstrained Cinryze supply is a top priority.”
(Source: Shire)

2017-10-27T23:11:50+00:00